0

540788

ASPIRA

img img img img
No Data Available

Aspira Pathlab & Diagnostics L Share Price Update

As of the latest trading session, Aspira Pathlab & Diagnostics L is trading at ₹64.97, up by ₹0.23 or 0.35% from its previous close. The stock has moved between ₹62.10 and ₹74.00 today. Over the past year, the stock has delivered a return of -4.00%. In the last month, it has returned 16.29%.

Investment Returns

Over 1 Month 16.29% Over 3 Months 1.96% Over 6 Months 3.09% Over 1 Year -4.00%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Aspira Pathlab & Diagnostics L fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 66.90
  • P/E Ratio (TTM) 45.42
  • Beta 0.00
  • Book Value / share 14.01
  • Return on equity 16.88%
  • EPS (TTM) 1.43
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -1.56
info icon alternate text

Aspira Pathlab & Diagnostics L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 5.12
Operating Expense 6.81
Net Profit -1.56
Net Profit Margin (%) -30.46
Earnings Per Share (EPS) -1.52
EBITDA -1.08
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 8.09
Operating Expense 6.39
Net Profit 1.84
Net Profit Margin (%) 22.74
Earnings Per Share (EPS) 1.78
EBITDA 2.34
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 5.25
Operating Expense 4.88
Net Profit 0.47
Net Profit Margin (%) 8.95
Earnings Per Share (EPS) 0.46
EBITDA 0.92
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 5.78
Operating Expense 5.18
Net Profit 0.72
Net Profit Margin (%) 12.45
Earnings Per Share (EPS) 0.70
EBITDA 1.18
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 5.41
Operating Expense 5.12
Net Profit 0.38
Net Profit Margin (%) 7.02
Earnings Per Share (EPS) 0.37
EBITDA 0.86
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 22.00
Operating Expense 20.32
Net Profit 2.07
Net Profit Margin (%) 9.40
Earnings Per Share (EPS) 2.01
EBITDA 3.91
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 13.20
Operating Expense 16.30
Net Profit -2.67
Net Profit Margin (%) -20.22
Earnings Per Share (EPS) -2.60
EBITDA -0.75
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 14.46
Operating Expense 14.87
Net Profit -0.09
Net Profit Margin (%) -0.62
Earnings Per Share (EPS) -0.09
EBITDA 1.92
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 19.54
Operating Expense 15.18
Net Profit 4.46
Net Profit Margin (%) 22.82
Earnings Per Share (EPS) 4.33
EBITDA 6.47
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 15.21
Operating Expense 14.03
Net Profit 1.38
Net Profit Margin (%) 9.07
Earnings Per Share (EPS) 1.45
EBITDA 3.71
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.03
ROE % 16.47
ROCE % 11.47
Total Debt to Total Equity 0.15
EBITDA Margin 17.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 5.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.15
EBITDA Margin -5.76
Particulars MAR 2025 (Values in Cr)
Book Value / Share 7.08
ROE % 16.88
ROCE % 11.71
Total Debt to Total Equity 0.15
EBITDA Margin 17.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 5.07
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.16
EBITDA Margin -5.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 7.60
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.20
EBITDA Margin 13.28
Particulars MAR 2022 (Values in Cr)
Book Value / Share 7.64
ROE % 23.08
ROCE % 17.56
Total Debt to Total Equity 0.19
EBITDA Margin 33.11
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.29
ROE % 15.17
ROCE % 11.51
Total Debt to Total Equity 0.70
EBITDA Margin 24.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.14
Total Assets 17.46
Total Liabilities 17.46
Total Equity 12.16
Share Outstanding 1
Price to Book Ratio 12.04
Return on Assets (%) 11.58
Return on Capital (%) 15.12
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.38
Total Assets 14.70
Total Liabilities 14.70
Total Equity 10.14
Share Outstanding 1
Price to Book Ratio 6.11
Return on Assets (%) -18.16
Return on Capital (%) -23.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.14
Total Assets 17.51
Total Liabilities 17.51
Total Equity 12.21
Share Outstanding 1
Price to Book Ratio 12.04
Return on Assets (%) 11.83
Return on Capital (%) 15.44
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.38
Total Assets 14.70
Total Liabilities 14.70
Total Equity 10.14
Share Outstanding 1
Price to Book Ratio 6.11
Return on Assets (%) -18.16
Return on Capital (%) -23.82
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.34
Total Assets 17.34
Total Liabilities 17.34
Total Equity 12.75
Share Outstanding 1
Price to Book Ratio 3.66
Return on Assets (%) -0.51
Return on Capital (%) -0.65
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.64
Total Assets 18.13
Total Liabilities 18.13
Total Equity 12.78
Share Outstanding 1
Price to Book Ratio 8.48
Return on Assets (%) 24.58
Return on Capital (%) 32.67
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.18
Total Assets 11.77
Total Liabilities 11.77
Total Equity 8.31
Share Outstanding 1
Price to Book Ratio 8.66
Return on Assets (%) 11.72
Return on Capital (%) 14.44
Particulars MAR 2025 (Values in Cr)
Net Income 2.02
Cash from Operations 1.82
Cash from Investing 0.11
Cash from Financing -0.99
Net change in Cash 0.94
Free Cash Flow 2.17
Particulars MAR 2024 (Values in Cr)
Net Income -2.67
Cash from Operations 1.05
Cash from Investing 0.13
Cash from Financing -0.95
Net change in Cash 0.23
Free Cash Flow 1.31
Particulars MAR 2025 (Values in Cr)
Net Income 2.07
Cash from Operations 1.87
Cash from Investing 0.06
Cash from Financing -0.99
Net change in Cash 0.94
Free Cash Flow 2.22
Particulars MAR 2024 (Values in Cr)
Net Income -2.67
Cash from Operations 1.05
Cash from Investing 0.13
Cash from Financing -0.95
Net change in Cash 0.23
Free Cash Flow 1.31
Particulars MAR 2023 (Values in Cr)
Net Income -0.08
Cash from Operations -0.01
Cash from Investing 0.15
Cash from Financing -0.93
Net change in Cash -0.78
Free Cash Flow 0.11
Particulars MAR 2022 (Values in Cr)
Net Income 4.45
Cash from Operations 2.03
Cash from Investing -0.51
Cash from Financing -1.35
Net change in Cash 0.16
Free Cash Flow 2.62
Particulars MAR 2021 (Values in Cr)
Net Income 1.38
Cash from Operations 5.67
Cash from Investing -0.09
Cash from Financing -2.17
Net change in Cash 3.40
Free Cash Flow 5.79
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTERPRISE LT 7639.20 60.47 12.08 109839.98 6680.00 8099.00
FORTIS MALAR HOSPITALS LIMITED 56.00 23.14 3.05 104.95 40.75 81.00
SHREE PACETRONIX LTD. 135.36 20.42 2.99 50.76 66.10 283.15
TRANSGENE BIOTEK LTD. 2.75 0.00 2.26 20.84 1.83 5.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTERPRISE LT 7639.20 75.63 11.79 109839.98 6680.00 8099.00
[-] 0.0 0.0 0.0 0.0 0.0 0.0
CHENNAI MEENAKSHI MULTISPECIAL 39.20 0.00 -11.39 29.28 30.02 57.48
KOVAI MEDICAL CENTER & HO 5665.45 26.28 5.20 6198.00 5010.00 6725.00

Aspira Pathlab & Diagnostics L shareholding pattern

Holding
81.6%
18.39%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Aspira Pathlab & Diagnostics L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
64.95 0.32 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 64.10
  • 26 Days 60.10
  • 10 Days 62.50
  • 50 Days 59.80
  • 12 Days 62.00
  • 100 Days 60.80
  • 20 Days 60.60
  • 200 Days 61.00
64.33 PIVOT
First Support 63.91 First Resistance 65.15 Second Support 63.09 Second Resistance 65.57 Third Support 62.67 Third Resistance 66.39
RSI 59.53 ADX 22.69 MACD 1.89 Williams % R -36.20 Commodity Channel Index (CCI) 149.52
Date 2026-04-30 Week 2417.00 Same Day 1139.00 Month 1497.00
1 Year 0.01 3 Year 0.02
Over 1 Month
16.29% down
Over 1 Year
-4.00% down
Over 3 Months
1.96% down
Over 3 Years
25.32% down
Over 6 Months
3.09% down
Over 5 Years
16.78% down

Aspira Pathlab & Diagnostics L Corporate Actions

Top Gainers

Top Losers

Aspira Pathlab & Diagnostics L Share Price

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973. ASDL is a leading pathology specialist, with Pan-India presence. It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses. The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services.

Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers. Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.

ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results. During the year 2016, the Company commenced its business activities of diagnostic center & pathology from November 2016 onwards by acquiring running business activities of 'Ankur Pathology Laboratory'.

Aspira is focused on establishing itself as a strong regional player before scaling up its operations. Although, it follow an asset light model, other costs are significantly high. Most of these cost is front ended and the payback period is high. It is therefore working on building the right systems and optimize the cost. It is adopting new technologies that improve customer experience. Some of these are use of Chatbot, improving website, implementing patient engagement platform, Customer Service, etc. Also concentrating more on HLM, trying to expand area by targeting newly setup hospitals and laboratory and trying to achieve more technology and advancement.

Company floated an associate LLP i.e 'Aspira DNA Diagnostics Gujarat LLP' on April 2, 2024.

Parent organization Indian Private
NSE symbol [-]
Founded 1973
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Aspira Pathlab & Diagnostics Ltd?

Answer Field

Aspira Pathlab & Diagnostics Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 64.95 as on Apr 30 2026 03:02 PM.

What is the Market Cap of Aspira Pathlab & Diagnostics Ltd Share?

Answer Field

The market cap of Aspira Pathlab & Diagnostics Ltd for NSE ₹ 0.00 & for BSE ₹ 66.90 as on Apr 30 2026 03:02 PM.

What is the 52 Week High and Low of Aspira Pathlab & Diagnostics Ltd?

Answer Field

The 52 Week High and Low of Aspira Pathlab & Diagnostics Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 81.00 and ₹ 49.00.

What is 1 year return for Aspira Pathlab & Diagnostics Ltd?

Answer Field

The 1 year returns on the stock has been -4.00%.

What is the P/E Ratio of Aspira Pathlab & Diagnostics Ltd Share?

Answer Field

As on Apr 30 2026 03:02 PM the price-to-earnings (PE) ratio for Aspira Pathlab & Diagnostics Ltd share is 45.42.

What is the PB ratio of Aspira Pathlab & Diagnostics Ltd Share?

Answer Field

As on Apr 30 2026 03:02 PM, the price-to-book (PB) ratio for Aspira Pathlab & Diagnostics Ltd share is 14.01.

How to Buy Aspira Pathlab & Diagnostics Ltd Share?

Answer Field

You can trade in Aspira Pathlab & Diagnostics Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Aspira Pathlab & Diagnostics Ltd Share on Bajaj Broking App?

Answer Field

To buy Aspira Pathlab & Diagnostics Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Aspira Pathlab & Diagnostics Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|